Sanofi official: Ex DOH Sec Garin LYING

dengue Pnoy sanfi beijing

At a House of Representatives committee investigation on the PHP 3.5 BILLION dengue vaccine SCAM, a Sanofi official who was in the December 2015 meeting with former President Aquino in Paris, France, stated that the dengue vaccine was in the agenda. Aquino Secretary of Health Garin previously stated that she was not in the meeting. Upon being shown photos of her with P-Noy and the Sanofi officials, she reversed herself but then said that Dengvaxia was NOT among the topics talked about. This latest revelation in the Lower House puts another BLACK EYE in the testimony of Garin, who has been caught time and again as being CONSISTENTLY EVASIVE and LYING THROUGH HER TEETH.

The Philippine ambassador to France also issued a memorandum on the discussion with President Aquino speaking about Dengvaxia.

**********

AQUINO DOH SECRETARY GARIN ADMITS MEETING WITH SANOFI OFFICIALS IN PARIS IN 2016

In an EVASIVE and CONVOLUTED manner, Aquino Administration Department of Health Secretary Garin FINALLY ADMITTED meeting with officials of vaccine maker Sanofi in Paris with President Aquino in December 2015.  She also said that negotiations for the controversial Dengue vaccine was initiated by her predecessor Dr. Enrique Ona. She claimed that she too was surprised that Sanofi issued a negative memorandum about the Sanofi product. Initial studies indicate that the vaccine may be ineffective and could, in fact, cause a MORE SEVERE manifestation of the disease in comparison to dengue patients that have not previously been vaccinated. Dengue is a major killer in the Philippines which means that 700,000 vaccinated school children will be at a greater risk of serious infection which could result in DEATH.

*******************

AQUINO ORDERED HEALTH SECRETARY GARIN TO BUY THE P3.5-B DEFECTIVE DENGUE VACCINE

It was former President Benigno Aquino 3rd who ordered his Health Secretary then, Jannete Garin, to purchase P3.5 billion worth of the French firm Sanofi Pasteur’s controversial anti-dengue vaccine Dengvaxia, sources in the government disclosed. He also ordered his Budget Secretary Florencio Abad to look for, and release, the P3.5 billion funding for it, as the health department didn’t have such allocation in its 2016 budget.

Garin herself had hesitated to order the vaccines in 2015 because it still didn’t have clearances from reputable medical bodies, including the World Health Organization. Even her officials very strongly advised her against it.

The Philippines is the only country to undertake a mass immunization program using the Dengvaxia vaccine – involving 700,000 grade-four students during the last three months of the Aquino regime, with a total of 1 million planned. Although Mexican and Brazilian authorities have licensed the sale of the vaccine, they haven’t launched such mass, effectively compulsory, vaccination using the Dengvaxia vaccine.

President Duterte’s then Health Secretary Paulyn Ubial put the Dengvaxia program on hold in July, on grounds that it had not been proven safe yet.

The company itself, though, issued a warning on its own vaccine Nov. 29, reporting that it found out that if Dengvaxia “is given to individuals who haven’t been exposed to dengue, they could get more serious infections when they encounter the virus naturally.”

That means that if a child had never been exposed to, or sick with, dengue but he was inoculated with the Dengvaxia, and he then contracts the mosquito-borne illness, he would be worse off, and could even face death. Most of the 700,000 children inoculated with Dengvaxia had never had dengue. Some 700,000 Filipino children, therefore, now have the potentially deadly serum in their blood. Already, four children who had been inoculated with Dengvaxia and who caught dengue had reportedly died.

Even before it’s alarming findings, Sanofi had recommended the vaccine to be used only in populations among whom at least 50 percent have contracted the dengue disease. Dengue has been prevalent only in a few areas in the country, with total incidence of only 0.01 percent of the total Philippine population.

WHO report
The World Health Organization, the UN authority on the safety of drugs, had not approved the vaccine. It finally reported in July 2016 that countries should consider the introduction of the dengue vaccine “only in geographic settings (national or subnational) where epidemiological data indicate a high burden of the disease.”

“There’s no way for Garin to get Budget Secretary Florencio Abad to release government funds to P3.5 billion in a month’s time to buy a single type of vaccine, one that was not approved by reputable local and international bodies, and bought from one company,” a government source said. The health departments’total budget annually for all vaccines it buys is about P3 billion, he pointed out. The source quipped: “How much is 10 percent of P3.5 billion?”

Aquino’s P3.5 billion ($70 million) purchase of Sanofi’s Dengvaxia – P3,000 for the three-doses required for each recipient – was a life-saver of sorts for the French firm. It spent $1.5 billion in 20 years to develop the vaccine, but had sold only $21 million, with the Philippines’ $70 million purchase giving it a financial boost, as well as the worldwide advertisement for it. Sanofi was racing against time, given that at least four other anti-dengue vaccines are being developed by competitors.

Aquino’s order to buy the Dengvaxia vaccines was given right after his December 1, 2015 meeting with top Sanofi officials, who included its CEO Olivier Charmeil in Paris, during a three-day visit there to attend the United Nations’ Climate Change Conference.

“I want this fast-tracked please,” Aquino reportedly told Garin as he stared intently at her, in hearing distance of Cabinet members who accompanied him and of the Sanofi officials, referring to the French firm’s lobbying for the purchase of the Dengvaxia vaccines. With Aquino in that meeting, aside from Garin, were finance secretary Cesar Purisima, Trade and Industry Gregory Domingo, Transportation Secretary Joseph Abaya, and officials of the Philippine embassy in Paris.

A press release by the Presidential Communications Operations Office (PCOO) on that meeting reported: “Aquino had a business meeting on Tuesday with officials of Sanofi Pasteur for the introduction of a dengue vaccine in the Philippines as the French pharmaceutical company moves toward completing the clinical trials for the vaccine….”

Malacañang for Sanofi

The Malacañang statement was practically a press release for Sanofi’s product, gushing: “The vaccine had completed phase 3 (advanced, pre-product launch) clinical studies in 2014” and that it passed research phases in the Philippines, reflecting high levels of research competence and capability.” As it turned out, though, the World Health Organization had not cleared the vaccine, and clinical trials were still ongoing at that time.

Strangely, when Congress started investigating the controversy, Garin in effect claimed that Aquino’s information officials were lying: “It was not a meeting between Sanofi and President Aquino (but) the usual time where [sic]the president will allow himself to face the business community. The dengue vaccine issue was not discussed.”

Aquino had demonstrated extraordinary interest in the health department’s purchase of the Dengvaxia vaccine: It was the second time he met with the Sanofi officials.

He found time during the hectic APEC meeting in Beijing, China to meet with Sanofi officials, headed by the firm’s senior vice president for Asia Jean-luc Lowinski on Nov 9, 2014. The Sanofi officials were the only businessmen Aquino met with in Beijing. A press release by the Presidential Broadcast Staff reported at that time that Aquino discussed “Sanofi’s progress in developing a dengue vaccine for affected towns in the Philippines.”

Senator Richard Gordon, chairman of the Blue Ribbon Committee, when he was investigating the controversy last year pointed out the suspicious Dengvaxia purchase: “December 2, there was a meeting in Paris (between Aquino and the Sanofi executives); by December 22, the Food and Drug Administration approved the vaccine; by December 29, the Special Allotment Release Order for P3.5 billion was issued.” Talk of a midnight deal.

Gordon added: “The vaccine purchase was never budgeted by the health department in 2014, 2015, 2016 and also in 2017. They only requested it in November of 2015. The budget department found the money by declaring ‘savings’ from personnel salaries.”

This dengue vaccine corruption is of that sickening Yellow template: A noble cause is used to conceal graft of mammoth proportions. This case, though, could be the worst, as it has put the lives of our 700,000 mostly poor children on the line.

Manila Times December 4, 2017

 

Red flags on Dengvaxia ignored, health reform advocate says

dengue Pnoy sanfi beijing

MANILA, Philippines — Health advocates and experts had cautioned former Health Secretary Janette Garin over the safety of Dengvaxia but their warnings were ignored, a health reform advocate said Tuesday.

Dr. Anthony Leachon, former member of the Department of Health Expert Panel on Dengue, said that experts questioned the “premature” mass vaccination in 2016, citing that its safety and cost-effectiveness had not been established.

Leachon, in an interview on ANC, said that the introduction of the dengue vaccine should have been done on a controlled scale.

“When you launch a product, it will be exposed to about 10,000 to 20,000 kids and doctors will supervise so they can report side effects,” he said, noting it usually takes three years to prepare a community for a new vaccine.

“[But they proceeded with] mass vaccination. Safety issues were alerted by health advocates and scientists in the country but you ignored that,” Leachon said.

DOH suspended the mass immunization program on December 1, shortly after manufacturer Sanofi Pasteur disclosed it had found in post-trial tests that the vaccine poses a threat to those who had no prior dengue infection.

More than 860,000 people have been vaccinated with Dengvaxia. Over 830,000 children were vaccinated with Dengvaxia in schools and communities, while another 32,000 people were immunized in private hospitals.

Overpriced vaccines?          

Leachon said that Dr. Hilton Lam of the Formulary Executive Council conducted a cost-effectiveness study of the vaccine and found that it should be P655 per dose. The government sold it at P1,000 per dose.

“We thought it was bloated a little bit because the study did not consider potential side effects of the drug,” Leachon said.

He added that Dengvaxia is more expensive in the Philippines than in other countries.

During the Senate probe into the questionable purchase of the P3.5 billion worth of vaccines, Garin said that the country purchased the vaccine at a lower price ($20 per dose) than Brazil ($30 per dose).

Leachon, moreover, said that Garin and former president Benigno Aquino III should be held accountable.

“Any problem of this magnitude stops at the highest point of leadership at the Department of Health. Now of this particular magnitude where 800,000 kids [are affected], then the buck stops at the level of the office of the president,” he said.

Garin insisted that there was no corruption involved in the purchase of the dengue vaccines and that it was not hastily implemented.

“It’s not a midnight deal. Everything was above board,” she said.

She added that the decision to procure Dengvaxia was not a personal decision, but an “institutional decision.”

“We decided based on the data available at the time with the desire to fight dengue,” Garin said.

By Gaea Katreena Cabico (philstar.com) December 12, 2017

*******************

RELATED ARTICLE: https://balitangbalita.com/2017/12/11/sanofi-dengue-vaccine-php-3-5-billion-scam-ex-president-aquino-and-former-doh-secretary-garin-liable/

SANOFI DENGUE VACCINE PHP 3.5 BILLION SCAM: EX-PRESIDENT AQUINO AND FORMER DOH SECRETARY GARIN LIABLE

At the Senate investigation on the PHP 3.5 Billion Sanofi Dengue Vaccine SCAM, it was established that the experimental vaccine had not yet completed the Phase 4 stage (controlled launch or scaled down implementation) usually in the ten to twenty thousand beneficiary level and needing one to two years to complete so as to monitor possible ADVERSE EFFECTS or REACTIONS. Instead the roll out was made to more than 700,000 grade four students (out of a planned one million ten year olds).

Former Secretary of Health Ubial, who stopped the program stated that it is bad practice to do a massive public mobilization and vaccination using a new product in an election year. Health experts were unanimous that there was a RUSH to PURCHASE, specifically prodded by then President Aquino and then Health Secretary Garin. P-Noy met with Sanofi officials (for the second time) in December 2015 and it was also in the same month that the Food and Drug Administration (under the Department of Health) approved Sanofi’s Dengvaxia. President Aquino issued a memorandum order to the DBM to use personnel savings (from the Philippine budget) to fund the vaccine purchase.  By the end of the month the Department of Budget Management (DBM under then Secretary Abad) had issued a S.A.R.O. (special allotment release order).

Senate Blue Ribbon Committee Chair Senator Richard Gordon will look into the possible VIOLATION by President Aquino in the use of a S.A.R.O. to secure funding when a supplemental budget (though the House of Representatives and the Senate) route should have been the way to go.

Senator Gordon also cited a number of resolved cases where Sanofi officials were found guilty of BRIBERY in Germany and fined FORTY MILLION U. S. dollars. In the United States, Sanofi officials were fined ONE HUNDRED NINE MILLION U.S. dollars also for BRIBERY.

The current stage of the Senate investigation is focused on the SAFETY issues of the Sanofi Dengue vaccine. The next stage would tackle the financial aspects of the deal, specifically the bidding process (when the Formulary had not yet issued a certification), the HIGH COST of the product, the use of a single supplier, conflict of interest (in the FDA, FEC and the DOH where members used to work  for international pharmaceutical firms) plus the issue on whether baseline serological tests should have been done prior to administering the vaccine (which was scrapped due to high costs). Next Committee meeting will look into the LEGAL ASPECTS of ACCOUNTABILITY (on whether the vaccination program was pushed through for propaganda purposes (for the 2016 national elections) and/or to generate FINANCIAL RESOURCES for election purposes or personal gain. Ex President Aquino was SPECIFICALLY named.

Senator Gordon mentioned that a witness branded the vaccination program as a BETRAYAL of the Filipino people, with kids being used as GUINEA PIGS or LABORATORY RATS.

#DengueVaccine #Dengvaxia #PresidentAquino #DepartmentOfHealth

 

 

Sanofi Dengue Vaccine PHP 3.5 Billion SCAM: Ex-President Aquino and former DOH Secretary Garin LIABLE

At the Senate investigation on the PHP 3.5 Billion Sanofi Dengue Vaccine SCAM, it was established that the experimental vaccine had not yet completed the Phase 4 stage (controlled launch or scaled down implementation) usually in the ten to twenty thousand beneficiary level and needing one to two years to complete so as to monitor possible ADVERSE EFFECTS or REACTIONS. Instead the roll out was made to more than 700,000 grade four students (out of a planned one million ten year olds).

dengue Pnoy Garin

Former Secretary of Health Ubial, who stopped the program stated that it is bad practice to do a massive public mobilization and vaccination using a new product in an election year. Health experts were unanimous that there was a RUSH to PURCHASE, specifically prodded by then President Aquino and then Health Secretary Garin. P-Noy met with Sanofi officials (for the second time) in December 2015 and it was also in the same month that the Food and Drug Administration (under the Department of Health) approved Sanofi’s Dengvaxia. President Aquino issued a memorandum order to the DBM to use personnel savings (from the Philippine budget) to fund the vaccine purchase.  By the end of the month the Department of Budget Management (DBM under then Secretary Abad) had issued a S.A.R.O. (special allotment release order).

Senate Blue Ribbon Committee Chair Senator Richard Gordon will look into the possible VIOLATION by President Aquino in the use of a S.A.R.O. to secure funding when a supplemental budget (though the House of Representatives and the Senate) route should have been the way to go.

Senator Gordon also cited a number of resolved cases where Sanofi officials were found guilty of BRIBERY in Germany and fined FORTY MILLION U. S. dollars. In the United States, Sanofi officials were fined ONE HUNDRED NINE MILLION U.S. dollars also for BRIBERY.

The current stage of the Senate investigation is focused on the SAFETY issues of the Sanofi Dengue vaccine. The next stage would tackle the financial aspects of the deal, specifically the bidding process (when the Formulary had not yet issued a certification), the HIGH COST of the product, the use of a single supplier, conflict of interest (in the FDA, FEC and the DOH where members used to work  for international pharmaceutical firms) plus the issue on whether baseline serological tests should have been done prior to administering the vaccine (which was scrapped due to high costs). Next Committee meeting will look into the LEGAL ASPECTS of ACCOUNTABILITY (on whether the vaccination program was pushed through for propaganda purposes (for the 2016 national elections) and/or to generate FINANCIAL RESOURCES for election purposes or personal gain. Ex President Aquino was SPECIFICALLY named.

Senator Gordon mentioned that a witness branded the vaccination program as a BETRAYAL of the Filipino people, with kids being used as GUINEA PIGS or LABORATORY RATS.

 

 

 

Aquino DOH Secretary Garin ADMITS meeting with Sanofi officials in Paris in 2016

 

dengue Pnoy sanfi beijing

In an EVASIVE and CONVOLUTED manner, Aquino Administration Department of Health Secretary Garin FINALLY ADMITTED meeting with officials of vaccine maker Sanofi in Paris with President Aquino in December 2015.  She also said that negotiations for the controversial Dengue vaccine was initiated by her predecessor Dr. Enrique Ona. She claimed that she too was surprised that Sanofi issued a negative memorandum about the Sanofi product. Initial studies indicate that the vaccine may be ineffective and could, in fact, cause a MORE SEVERE manifestation of the disease in comparison to dengue patients that have not previously been vaccinated. Dengue is a major killer in the Philippines which means that 700,000 vaccinated school children will be at a greater risk of serious infection which could result in DEATH.

*******************

AQUINO ORDERED HEALTH SECRETARY GARIN TO BUY THE P3.5-B DEFECTIVE DENGUE VACCINE

It was former President Benigno Aquino 3rd who ordered his Health Secretary then, Jannete Garin, to purchase P3.5 billion worth of the French firm Sanofi Pasteur’s controversial anti-dengue vaccine Dengvaxia, sources in the government disclosed. He also ordered his Budget Secretary Florencio Abad to look for, and release, the P3.5 billion funding for it, as the health department didn’t have such allocation in its 2016 budget.

Garin herself had hesitated to order the vaccines in 2015 because it still didn’t have clearances from reputable medical bodies, including the World Health Organization. Even her officials very strongly advised her against it.

The Philippines is the only country to undertake a mass immunization program using the Dengvaxia vaccine – involving 700,000 grade-four students during the last three months of the Aquino regime, with a total of 1 million planned. Although Mexican and Brazilian authorities have licensed the sale of the vaccine, they haven’t launched such mass, effectively compulsory, vaccination using the Dengvaxia vaccine.

President Duterte’s then Health Secretary Paulyn Ubial put the Dengvaxia program on hold in July, on grounds that it had not been proven safe yet.

The company itself, though, issued a warning on its own vaccine Nov. 29, reporting that it found out that if Dengvaxia “is given to individuals who haven’t been exposed to dengue, they could get more serious infections when they encounter the virus naturally.”

That means that if a child had never been exposed to, or sick with, dengue but he was inoculated with the Dengvaxia, and he then contracts the mosquito-borne illness, he would be worse off, and could even face death. Most of the 700,000 children inoculated with Dengvaxia had never had dengue. Some 700,000 Filipino children, therefore, now have the potentially deadly serum in their blood. Already, four children who had been inoculated with Dengvaxia and who caught dengue had reportedly died.

Even before it’s alarming findings, Sanofi had recommended the vaccine to be used only in populations among whom at least 50 percent have contracted the dengue disease. Dengue has been prevalent only in a few areas in the country, with total incidence of only 0.01 percent of the total Philippine population.

WHO report
The World Health Organization, the UN authority on the safety of drugs, had not approved the vaccine. It finally reported in July 2016 that countries should consider the introduction of the dengue vaccine “only in geographic settings (national or subnational) where epidemiological data indicate a high burden of the disease.”

“There’s no way for Garin to get Budget Secretary Florencio Abad to release government funds to P3.5 billion in a month’s time to buy a single type of vaccine, one that was not approved by reputable local and international bodies, and bought from one company,” a government source said. The health departments’total budget annually for all vaccines it buys is about P3 billion, he pointed out. The source quipped: “How much is 10 percent of P3.5 billion?”

Aquino’s P3.5 billion ($70 million) purchase of Sanofi’s Dengvaxia – P3,000 for the three-doses required for each recipient – was a life-saver of sorts for the French firm. It spent $1.5 billion in 20 years to develop the vaccine, but had sold only $21 million, with the Philippines’ $70 million purchase giving it a financial boost, as well as the worldwide advertisement for it. Sanofi was racing against time, given that at least four other anti-dengue vaccines are being developed by competitors.

Aquino’s order to buy the Dengvaxia vaccines was given right after his December 1, 2015 meeting with top Sanofi officials, who included its CEO Olivier Charmeil in Paris, during a three-day visit there to attend the United Nations’ Climate Change Conference.

“I want this fast-tracked please,” Aquino reportedly told Garin as he stared intently at her, in hearing distance of Cabinet members who accompanied him and of the Sanofi officials, referring to the French firm’s lobbying for the purchase of the Dengvaxia vaccines. With Aquino in that meeting, aside from Garin, were finance secretary Cesar Purisima, Trade and Industry Gregory Domingo, Transportation Secretary Joseph Abaya, and officials of the Philippine embassy in Paris.

A press release by the Presidential Communications Operations Office (PCOO) on that meeting reported: “Aquino had a business meeting on Tuesday with officials of Sanofi Pasteur for the introduction of a dengue vaccine in the Philippines as the French pharmaceutical company moves toward completing the clinical trials for the vaccine….”

Malacañang for Sanofi

The Malacañang statement was practically a press release for Sanofi’s product, gushing: “The vaccine had completed phase 3 (advanced, pre-product launch) clinical studies in 2014” and that it passed research phases in the Philippines, reflecting high levels of research competence and capability.” As it turned out, though, the World Health Organization had not cleared the vaccine, and clinical trials were still ongoing at that time.

Strangely, when Congress started investigating the controversy, Garin in effect claimed that Aquino’s information officials were lying: “It was not a meeting between Sanofi and President Aquino (but) the usual time where [sic]the president will allow himself to face the business community. The dengue vaccine issue was not discussed.”

Aquino had demonstrated extraordinary interest in the health department’s purchase of the Dengvaxia vaccine: It was the second time he met with the Sanofi officials.

He found time during the hectic APEC meeting in Beijing, China to meet with Sanofi officials, headed by the firm’s senior vice president for Asia Jean-luc Lowinski on Nov 9, 2014. The Sanofi officials were the only businessmen Aquino met with in Beijing. A press release by the Presidential Broadcast Staff reported at that time that Aquino discussed “Sanofi’s progress in developing a dengue vaccine for affected towns in the Philippines.”

Senator Richard Gordon, chairman of the Blue Ribbon Committee, when he was investigating the controversy last year pointed out the suspicious Dengvaxia purchase: “December 2, there was a meeting in Paris (between Aquino and the Sanofi executives); by December 22, the Food and Drug Administration approved the vaccine; by December 29, the Special Allotment Release Order for P3.5 billion was issued.” Talk of a midnight deal.

Gordon added: “The vaccine purchase was never budgeted by the health department in 2014, 2015, 2016 and also in 2017. They only requested it in November of 2015. The budget department found the money by declaring ‘savings’ from personnel salaries.”

This dengue vaccine corruption is of that sickening Yellow template: A noble cause is used to conceal graft of mammoth proportions. This case, though, could be the worst, as it has put the lives of our 700,000 mostly poor children on the line.

Manila Times December 4, 2017

 

 

Dengue Vaccine VIRAL Pics: P-Noy, Garin and Sanofi

dengue Pnoy Garindengue SPOXdengue libre daang matuwiddengue india pricedengue gordon guinea pigdengue 700k no WHO

dengue 3.5 b scam pnoy

AQUINO ORDERED HEALTH SECRETARY GARIN TO BUY THE P3.5-B DEFECTIVE DENGUE VACCINE

It was former President Benigno Aquino 3rd who ordered his Health Secretary then, Jannete Garin, to purchase P3.5 billion worth of the French firm Sanofi Pasteur’s controversial anti-dengue vaccine Dengvaxia, sources in the government disclosed. He also ordered his Budget Secretary Florencio Abad to look for, and release, the P3.5 billion funding for it, as the health department didn’t have such allocation in its 2016 budget.

Garin herself had hesitated to order the vaccines in 2015 because it still didn’t have clearances from reputable medical bodies, including the World Health Organization. Even her officials very strongly advised her against it.

The Philippines is the only country to undertake a mass immunization program using the Dengvaxia vaccine – involving 700,000 grade-four students during the last three months of the Aquino regime, with a total of 1 million planned. Although Mexican and Brazilian authorities have licensed the sale of the vaccine, they haven’t launched such mass, effectively compulsory, vaccination using the Dengvaxia vaccine.

President Duterte’s then Health Secretary Paulyn Ubial put the Dengvaxia program on hold in July, on grounds that it had not been proven safe yet.

The company itself, though, issued a warning on its own vaccine Nov. 29, reporting that it found out that if Dengvaxia “is given to individuals who haven’t been exposed to dengue, they could get more serious infections when they encounter the virus naturally.”

That means that if a child had never been exposed to, or sick with, dengue but he was inoculated with the Dengvaxia, and he then contracts the mosquito-borne illness, he would be worse off, and could even face death. Most of the 700,000 children inoculated with Dengvaxia had never had dengue. Some 700,000 Filipino children, therefore, now have the potentially deadly serum in their blood. Already, four children who had been inoculated with Dengvaxia and who caught dengue had reportedly died.

Even before it’s alarming findings, Sanofi had recommended the vaccine to be used only in populations among whom at least 50 percent have contracted the dengue disease. Dengue has been prevalent only in a few areas in the country, with total incidence of only 0.01 percent of the total Philippine population.

WHO report
The World Health Organization, the UN authority on the safety of drugs, had not approved the vaccine. It finally reported in July 2016 that countries should consider the introduction of the dengue vaccine “only in geographic settings (national or subnational) where epidemiological data indicate a high burden of the disease.”

“There’s no way for Garin to get Budget Secretary Florencio Abad to release government funds to P3.5 billion in a month’s time to buy a single type of vaccine, one that was not approved by reputable local and international bodies, and bought from one company,” a government source said. The health departments’total budget annually for all vaccines it buys is about P3 billion, he pointed out. The source quipped: “How much is 10 percent of P3.5 billion?”

Aquino’s P3.5 billion ($70 million) purchase of Sanofi’s Dengvaxia – P3,000 for the three-doses required for each recipient – was a life-saver of sorts for the French firm. It spent $1.5 billion in 20 years to develop the vaccine, but had sold only $21 million, with the Philippines’ $70 million purchase giving it a financial boost, as well as the worldwide advertisement for it. Sanofi was racing against time, given that at least four other anti-dengue vaccines are being developed by competitors.

Aquino’s order to buy the Dengvaxia vaccines was given right after his December 1, 2015 meeting with top Sanofi officials, who included its CEO Olivier Charmeil in Paris, during a three-day visit there to attend the United Nations’ Climate Change Conference.

“I want this fast-tracked please,” Aquino reportedly told Garin as he stared intently at her, in hearing distance of Cabinet members who accompanied him and of the Sanofi officials, referring to the French firm’s lobbying for the purchase of the Dengvaxia vaccines. With Aquino in that meeting, aside from Garin, were finance secretary Cesar Purisima, Trade and Industry Gregory Domingo, Transportation Secretary Joseph Abaya, and officials of the Philippine embassy in Paris.

A press release by the Presidential Communications Operations Office (PCOO) on that meeting reported: “Aquino had a business meeting on Tuesday with officials of Sanofi Pasteur for the introduction of a dengue vaccine in the Philippines as the French pharmaceutical company moves toward completing the clinical trials for the vaccine….”

Malacañang for Sanofi

The Malacañang statement was practically a press release for Sanofi’s product, gushing: “The vaccine had completed phase 3 (advanced, pre-product launch) clinical studies in 2014” and that it passed research phases in the Philippines, reflecting high levels of research competence and capability.” As it turned out, though, the World Health Organization had not cleared the vaccine, and clinical trials were still ongoing at that time.

Strangely, when Congress started investigating the controversy, Garin in effect claimed that Aquino’s information officials were lying: “It was not a meeting between Sanofi and President Aquino (but) the usual time where [sic]the president will allow himself to face the business community. The dengue vaccine issue was not discussed.”

Aquino had demonstrated extraordinary interest in the health department’s purchase of the Dengvaxia vaccine: It was the second time he met with the Sanofi officials.

He found time during the hectic APEC meeting in Beijing, China to meet with Sanofi officials, headed by the firm’s senior vice president for Asia Jean-luc Lowinski on Nov 9, 2014. The Sanofi officials were the only businessmen Aquino met with in Beijing. A press release by the Presidential Broadcast Staff reported at that time that Aquino discussed “Sanofi’s progress in developing a dengue vaccine for affected towns in the Philippines.”

Senator Richard Gordon, chairman of the Blue Ribbon Committee, when he was investigating the controversy last year pointed out the suspicious Dengvaxia purchase: “December 2, there was a meeting in Paris (between Aquino and the Sanofi executives); by December 22, the Food and Drug Administration approved the vaccine; by December 29, the Special Allotment Release Order for P3.5 billion was issued.” Talk of a midnight deal.

Gordon added: “The vaccine purchase was never budgeted by the health department in 2014, 2015, 2016 and also in 2017. They only requested it in November of 2015. The budget department found the money by declaring ‘savings’ from personnel salaries.”

This dengue vaccine corruption is of that sickening Yellow template: A noble cause is used to conceal graft of mammoth proportions. This case, though, could be the worst, as it has put the lives of our 700,000 mostly poor children on the line.

Manila Times December 4, 2017

 

Aquino ordered Health Secretary Garin to buy the P3.5-B defective dengue vaccine

It was former President Benigno Aquino 3rd who ordered his Health Secretary then, Jannete Garin, to purchase P3.5 billion worth of the French firm Sanofi Pasteur’s controversial anti-dengue vaccine Dengvaxia, sources in the government disclosed. He also ordered his Budget Secretary Florencio Abad to look for, and release, the P3.5 billion funding for it, as the health department didn’t have such allocation in its 2016 budget.

dengue Pnoy sanfi beijing

Garin herself had hesitated to order the vaccines in 2015 because it still didn’t have clearances from reputable medical bodies, including the World Health Organization. Even her officials very strongly advised her against it.

The Philippines is the only country to undertake a mass immunization program using the Dengvaxia vaccine – involving 700,000 grade-four students during the last three months of the Aquino regime, with a total of 1 million planned. Although Mexican and Brazilian authorities have licensed the sale of the vaccine, they haven’t launched such mass, effectively compulsory, vaccination using the Dengvaxia vaccine.

President Duterte’s then Health Secretary Paulyn Ubial put the Dengvaxia program on hold in July, on grounds that it had not been proven safe yet.

The company itself, though, issued a warning on its own vaccine Nov. 29, reporting that it found out that if Dengvaxia “is given to individuals who haven’t been exposed to dengue, they could get more serious infections when they encounter the virus naturally.”

That means that if a child had never been exposed to, or sick with, dengue but he was inoculated with the Dengvaxia, and he then contracts the mosquito-borne illness, he would be worse off, and could even face death. Most of the 700,000 children inoculated with Dengvaxia had never had dengue. Some 700,000 Filipino children, therefore, now have the potentially deadly serum in their blood. Already, four children who had been inoculated with Dengvaxia and who caught dengue had reportedly died.

Even before it’s alarming findings, Sanofi had recommended the vaccine to be used only in populations among whom at least 50 percent have contracted the dengue disease. Dengue has been prevalent only in a few areas in the country, with total incidence of only 0.01 percent of the total Philippine population.

 WHO report
The World Health Organization, the UN authority on the safety of drugs, had not approved the vaccine. It finally reported in July 2016 that countries should consider the introduction of the dengue vaccine “only in geographic settings (national or subnational) where epidemiological data indicate a high burden of the disease.”

“There’s no way for Garin to get Budget Secretary Florencio Abad to release government funds to P3.5 billion in a month’s time to buy a single type of vaccine, one that was not approved by reputable local and international bodies, and bought from one company,” a government source said. The health departments’total budget annually for all vaccines it buys is about P3 billion, he pointed out. The source quipped: “How much is 10 percent of P3.5 billion?”

Aquino’s P3.5 billion ($70 million) purchase of Sanofi’s Dengvaxia – P3,000 for the three-doses required for each recipient – was a life-saver of sorts for the French firm. It spent $1.5 billion in 20 years to develop the vaccine, but had sold only $21 million, with the Philippines’ $70 million purchase giving it a financial boost, as well as the worldwide advertisement for it. Sanofi was racing against time, given that at least four other anti-dengue vaccines are being developed by competitors.

Aquino’s order to buy the Dengvaxia vaccines was given right after his December 1, 2015 meeting with top Sanofi officials, who included its CEO Olivier Charmeil in Paris, during a three-day visit there to attend the United Nations’ Climate Change Conference.

“I want this fast-tracked please,” Aquino reportedly told Garin as he stared intently at her, in hearing distance of Cabinet members who accompanied him and of the Sanofi officials, referring to the French firm’s lobbying for the purchase of the Dengvaxia vaccines. With Aquino in that meeting, aside from Garin, were finance secretary Cesar Purisima, Trade and Industry Gregory Domingo, Transportation Secretary Joseph Abaya, and officials of the Philippine embassy in Paris.

A press release by the Presidential Communications Operations Office (PCOO) on that meeting reported: “Aquino had a business meeting on Tuesday with officials of Sanofi Pasteur for the introduction of a dengue vaccine in the Philippines as the French pharmaceutical company moves toward completing the clinical trials for the vaccine….”

Malacañang for Sanofi

The Malacañang statement was practically a press release for Sanofi’s product, gushing: “The vaccine had completed phase 3 (advanced, pre-product launch) clinical studies in 2014” and that it passed research phases in the Philippines, reflecting high levels of research competence and capability.” As it turned out, though, the World Health Organization had not cleared the vaccine, and clinical trials were still ongoing at that time.

Strangely, when Congress started investigating the controversy, Garin in effect claimed that Aquino’s information officials were lying: “It was not a meeting between Sanofi and President Aquino (but) the usual time where [sic]the president will allow himself to face the business community. The dengue vaccine issue was not discussed.”

Aquino had demonstrated extraordinary interest in the health department’s purchase of the Dengvaxia vaccine: It was the second time he met with the Sanofi officials.

He found time during the hectic APEC meeting in Beijing, China to meet with Sanofi officials, headed by the firm’s senior vice president for Asia Jean-luc Lowinski on Nov 9, 2014. The Sanofi officials were the only businessmen Aquino met with in Beijing. A press release by the Presidential Broadcast Staff reported at that time that Aquino discussed “Sanofi’s progress in developing a dengue vaccine for affected towns in the Philippines.”

Senator Richard Gordon, chairman of the Blue Ribbon Committee, when he was investigating the controversy last year pointed out the suspicious Dengvaxia purchase: “December 2, there was a meeting in Paris (between Aquino and the Sanofi executives); by December 22, the Food and Drug Administration approved the vaccine; by December 29, the Special Allotment Release Order for P3.5 billion was issued.” Talk of a midnight deal.

Gordon added: “The vaccine purchase was never budgeted by the health department in 2014, 2015, 2016 and also in 2017. They only requested it in November of 2015. The budget department found the money by declaring ‘savings’ from personnel salaries.”

This dengue vaccine corruption is of that sickening Yellow template: A noble cause is used to conceal graft of mammoth proportions. This case, though, could be the worst, as it has put the lives of our 700,000 mostly poor children on the line.

Manila Times December 4, 2017